eCite Digital Repository

Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry

Citation

Jo, HE and Corte, TJ and Glaspole, I and Grainge, C and Hopkins, PMA and Moodley, Y and Reynolds, PN and Chapman, S and Walters, EH and Zappala, C and Allan, H and Keir, GJ and Cooper, WA and Mahar, AM and Ellis, S and MacAnsh, S and Goh, NS, Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry, BMC Pulmonary Medicine, 19, (1) pp. 84. ISSN 1471-2466 (2019) [Refereed Article]


Preview
PDF
780Kb
  

Copyright Statement

Copyright 2019 The Authors. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/

DOI: doi:10.1186/s12890-019-0846-2

Abstract

Background and objective: Gastroesophageal reflux disease (GORD) is highly prevalent in idiopathic pulmonary fibrosis (IPF) and may play a role in its pathogenesis. Recent IPF treatment guidelines suggest that all patients with IPF be considered for antacid therapy. However, emerging evidence suggests that antacid therapy does not improve IPF patient outcomes and may increase the risk of pulmonary infection.

Methods: Using prospectively collected data from the Australian IPF Registry including use of antacid therapy, GORD diagnosis and GORD symptoms, the relationship of these GORD variables to survival and disease progression was assessed. The severity of GORD symptoms using the frequency scale for symptoms of GORD (FSSG) and its relationships to outcomes was also assessed for the first time in an IPF cohort.

Results: Five hundred eighty-seven (86%) of the 684 patients in the Australian IPF Registry were eligible for inclusion. Patients were mostly male (69%), aged 71.0  8.5 years with moderate disease (FVC 81.7  21.5%; DLco 48.5  16.4%). Most patients were taking antacids (n = 384; 65%), though fewer had a diagnosis of GORD (n = 243, 41.4%) and typical GORD symptoms were even less common (n = 171, 29.1%). The mean FSSG score was 8.39  7.45 with 43% (n = 251) having a score > 8. Overall, there was no difference in survival or disease progression, regardless of antacid treatment, GORD diagnosis or GORD symptoms.

Conclusions: Neither the use of antacid therapy nor the presence of GORD symptoms affects longer term outcomes in IPF patients. This contributes to the increasing evidence that antacid therapy may not be beneficial in IPF patients and that GORD directed therapy should be considered on an individual basis to treat the symptoms of reflux.

Item Details

Item Type:Refereed Article
Keywords:idiopathic pulmonary fibrosis, gastroesophageal reflux disease, antacid, registry, cough
Research Division:Medical and Health Sciences
Research Group:Public Health and Health Services
Research Field:Epidemiology
Objective Division:Health
Objective Group:Public Health (excl. Specific Population Health)
Objective Field:Behaviour and Health
UTAS Author:Walters, EH (Professor Haydn Walters)
ID Code:134067
Year Published:2019
Deposited By:Medicine
Deposited On:2019-07-24
Last Modified:2019-08-05
Downloads:4 View Download Statistics

Repository Staff Only: item control page